<a href="https://laohu8.com/S/MBRX">Moleculin Biotech</a> Secures RAMPA Approval to Expand Phase 3 MIRACLE Clinical Trial into Georgia, Boosting Global Enrollment Efforts
Moleculin Biotech Inc., a late-stage pharmaceutical company specializing in treatments for challenging cancers and viral infections, has received regulatory approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for its Phase 2B/3 MIRACLE clinical trial. This pivotal trial, which investigates the combination of Annamycin and cytarabine for treating refractory or relapsed acute myeloid leukemia $(AML.AU)$ in adults, is set to expand globally with sites in the US, Europe, and the Middle East. Following recent approval from the European Medicines Agency $(EMA)$, Moleculin plans to enhance its enrollment efforts by adding 16 additional clinical sites in Europe and the US by the end of August, aiming for over 30 sites for Part A of the trial. The company anticipates reporting initial data from Part A in the second half of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-022386), on July 09, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。